GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 2 814 JPY -1.26% Market Closed
Market Cap: 140.9B JPY
Have any thoughts about
GNI Group Ltd?
Write Note

GNI Group Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GNI Group Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
GNI Group Ltd
TSE:2160
Cash from Investing Activities
-ÂĄ9.8B
CAGR 3-Years
-239%
CAGR 5-Years
-56%
CAGR 10-Years
-45%
PeptiDream Inc
TSE:4587
Cash from Investing Activities
ÂĄ9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Cash from Investing Activities
-ÂĄ13.1B
CAGR 3-Years
-179%
CAGR 5-Years
-34%
CAGR 10-Years
-1%
Pharma Foods International Co Ltd
TSE:2929
Cash from Investing Activities
-ÂĄ1.4B
CAGR 3-Years
-47%
CAGR 5-Years
-36%
CAGR 10-Years
-23%
S
StemRIM Inc
TSE:4599
Cash from Investing Activities
-ÂĄ4.8m
CAGR 3-Years
63%
CAGR 5-Years
6%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Cash from Investing Activities
-ÂĄ35m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
140.9B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 144.85 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

What is GNI Group Ltd's Cash from Investing Activities?
Cash from Investing Activities
-9.8B JPY

Based on the financial report for Jun 30, 2024, GNI Group Ltd's Cash from Investing Activities amounts to -9.8B JPY.

What is GNI Group Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-45%

Over the last year, the Cash from Investing Activities growth was -88%. The average annual Cash from Investing Activities growth rates for GNI Group Ltd have been -239% over the past three years , -56% over the past five years , and -45% over the past ten years .

Back to Top